2-Bromo-3-methylvaleranilide | 54730-73-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Bromo-3-methylvaleranilide
• 英文别名: 2-Methyl-valeriansaeure-anilid；3-methyl-valeric acid anilide；3-Methyl-valeriansaeure-anilid；β-Methyl-β-aethyl-propionsaeure-anilid；β-Methyl-n-valeriansaeure-anilid；3-methyl-N-phenylpentanamide
• CAS: 54730-73-3
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: XVSPVJAADFOMDG-UHFFFAOYSA-N

物化性质

• 熔点：
  84-85.5 °C
• 沸点：
  344.2±11.0 °C(Predicted)
• 密度：
  1.012±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Bromo-3-methylvaleranilide 在 sodium hydride 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 [2-(3-sec-Butyl-quinolin-2-ylsulfanyl)-ethyl]-dimethyl-amine
  参考文献：
  名称：

  Synthesis and 5-hydroxytryptamine antagonist activity of 2-[[2-(dimethylamino)ethyl]thio]-3-phenylquinoline and its analogs

  摘要：

  A series of 2-[(2-aminoethyl)thio]quinolines substituted at the 3-position with alkyl, aryl, or heteroaryl groups has been prepared in the search for novel and selective 5-HT2 antagonists. The affinity of the compounds for 5-HT1 receptor sites was measured by their ability to displace [3H]-5-HT from rat brain synaptosomes whereas the affinity for 5-HT2 receptor sites was measured by their ability to displace [3H]spiperone from synaptosomes prepared from rat brain cortex. The 5-HT2 antagonist properties of the compounds were measured in vivo by their antagonism of 5-hydroxytryptophan-induced head twitches in the mouse and by their antagonism of hyperthermia induced by fenfluramine (N-ethyl-alpha-methyl-m-(trifluoromethyl)phenethylamine hydrochloride) in the rat. The structure-activity relationships in this series are discussed and the properties of 2-[[2-(dimethylamino)ethyl]thio]-3-phenylquinoline hydrochloride (70) are highlighted.

  DOI：

  10.1021/jm00395a013
• 作为产物：
  描述：

  2-甲基-丁烯 在 铂 氢气 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 120.0 ℃ 、1.6 kPa 条件下， 生成 2-Bromo-3-methylvaleranilide
  参考文献：
  名称：

  Achmatowicz,O.; Zamojska,F., Roczniki Chemii, 1961, vol. 35, p. 201 - 220

  摘要：

  DOI：

文献信息

• 1,4-benzodiazepinones and their uses as CCK antagonists
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US20020183313A1

  公开（公告）日：2002-12-05

  Benzodiazepine derivatives of the formula: 1 wherein R 1 is heterocyclic(lower)alkyl which may have one or more suitable substituent(s), etc., R 2 is lower alkyl, etc., R 3 is indolyl, etc., R 4 is hydrogen, etc., or a pharmaceutically acceptable salt thereof, which are useful as a medicament.

  公式为1的苯二氮平衍生物，其中R1为杂环（较低）烷基，可以有一个或多个合适的取代基等，R2为较低的烷基等，R3为吲哚基等，R4为氢等，或其药学上可接受的盐，可用作药物。
• 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME
  申请人：Japan Tobacco Inc.

  公开号：EP0970954A1

  公开（公告）日：2000-01-12

  3-piperidyl-4-oxoquinazoline derivatives are provided, which is represented by the formula (I): wherein R represents an amino group or a cyclic amino group such as dibenzoazepine, each of which is substituted with a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, or the like, n is an integer of 1 to 4, R3 and R4 independently represents a hydrogen atom, a lower alkyl group, or the like, or a pharmaceutically acceptable salt thereof. Compounds (I) of the present invention have excellent MTP-inhibitory activity. Thus, these compounds not only inhibit formation of LDL that is a cause of arteriosclerotic diseases but also regulate TG, cholesterol, and lipoproteins such as LDL in the blood and regulate cellular lipids through regulation of MTP activity. They can also be used as a new type of preventive or therapeutic agents for hyperlipemia or arteriosclerotic diseases. Furthermore, they can be used as therapeutic or preventive agents for pancreatitis, obesity, hypercholesterolemia, and hypertriglyceridemia.

  提供了3-哌啶基-4-氧代喹唑啉衍生物，由式(I)表示： 其中 R 代表氨基或环状氨基，如二苯并氮杂卓，它们各自被取代或未被取代的芳基、取代或未被取代的杂芳基或类似基团取代，n 是 1 至 4 的整数，R3 和 R4 独立地代表氢原子、低级烷基或类似基团，或其药学上可接受的盐。本发明的化合物（I）具有优异的 MTP 抑制活性。因此，这些化合物不仅能抑制导致动脉硬化疾病的低密度脂蛋白的形成，还能调节血液中的总胆固醇、胆固醇和脂蛋白（如低密度脂蛋白），并通过调节 MTP 活性来调节细胞脂质。它们还可用作高脂血症或动脉硬化疾病的新型预防或治疗药物。此外，它们还可用作胰腺炎、肥胖症、高胆固醇血症和高甘油三酯血症的治疗或预防药物。
• Schwartz; Johnson, Journal of the American Chemical Society, 1931, vol. 53, p. 1065
  作者：Schwartz、Johnson

  DOI：——

  日期：——
• Hommelen, Bulletin des Societes Chimiques Belges, 1933, vol. 42, p. 243,249
  作者：Hommelen

  DOI：——

  日期：——
• Bentley, Journal of the Chemical Society, 1895, vol. 67, p. 265
  作者：Bentley

  DOI：——

  日期：——